These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29773641)

  • 1. IL1RAP potentiates multiple oncogenic signaling pathways in AML.
    Mitchell K; Barreyro L; Todorova TI; Taylor SJ; Antony-Debré I; Narayanagari SR; Carvajal LA; Leite J; Piperdi Z; Pendurti G; Mantzaris I; Paietta E; Verma A; Gritsman K; Steidl U
    J Exp Med; 2018 Jun; 215(6):1709-1727. PubMed ID: 29773641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
    Barreyro L; Will B; Bartholdy B; Zhou L; Todorova TI; Stanley RF; Ben-Neriah S; Montagna C; Parekh S; Pellagatti A; Boultwood J; Paietta E; Ketterling RP; Cripe L; Fernandez HF; Greenberg PL; Tallman MS; Steidl C; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Aug; 120(6):1290-8. PubMed ID: 22723552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
    Zhang Y; Park M; Ghoda LY; Zhao D; Valerio M; Nafie E; Gonzalez A; Ly K; Parcutela B; Choi H; Gong X; Chen F; Harada K; Chen Z; Nguyen LXT; Pichiorri F; Chen J; Song J; Forman SJ; Amanam I; Zhang B; Jin J; Williams JC; Marcucci G
    J Hematol Oncol; 2024 Aug; 17(1):67. PubMed ID: 39143574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis.
    De Boer B; Sheveleva S; Apelt K; Vellenga E; Mulder AB; Huls G; Jacob Schuringa J
    Haematologica; 2021 Dec; 106(12):3067-3078. PubMed ID: 33121233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
    Askmyr M; Ågerstam H; Hansen N; Gordon S; Arvanitakis A; Rissler M; Juliusson G; Richter J; Järås M; Fioretos T
    Blood; 2013 May; 121(18):3709-13. PubMed ID: 23479569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nobiletin Down-Regulates c-KIT Gene Expression and Exerts Antileukemic Effects on Human Acute Myeloid Leukemia Cells.
    Chen PY; Chen YT; Gao WY; Wu MJ; Yen JH
    J Agric Food Chem; 2018 Dec; 66(51):13423-13434. PubMed ID: 30507186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Role of IL1RAP on Tumor Microenvironment-Related Inflammatory Factors in Stomach Adenocarcinoma.
    Lv Q; Xia Q; Li A; Wang Z
    Technol Cancer Res Treat; 2021; 20():1533033821995282. PubMed ID: 33602046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia.
    Geyh S; Rodríguez-Paredes M; Jäger P; Khandanpour C; Cadeddu RP; Gutekunst J; Wilk CM; Fenk R; Zilkens C; Hermsen D; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
    Leukemia; 2016 Mar; 30(3):683-91. PubMed ID: 26601782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.
    Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DD
    Mol Cancer; 2014 Apr; 13():79. PubMed ID: 24708856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyphyllin I Inhibits Proliferation and Induces Apoptosis by Downregulating AML1-ETO and Suppressing C-KIT/Akt Signaling in t(8;21) Acute Myeloid Leukemia.
    Chai Y; Si Y; Xu J; Xiang Y; Zhao H; Si Y; Zhang T; Liu Y
    Chem Biodivers; 2018 Nov; 15(11):e1800314. PubMed ID: 30194712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
    Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
    Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
    Chatterjee A; Ghosh J; Ramdas B; Mali RS; Martin H; Kobayashi M; Vemula S; Canela VH; Waskow ER; Visconte V; Tiu RV; Smith CC; Shah N; Bunting KD; Boswell HS; Liu Y; Chan RJ; Kapur R
    Cell Rep; 2014 Nov; 9(4):1333-48. PubMed ID: 25456130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V.
    Rai S; Tanaka H; Suzuki M; Espinoza JL; Kumode T; Tanimura A; Yokota T; Oritani K; Watanabe T; Kanakura Y; Matsumura I
    Nat Commun; 2020 Aug; 11(1):4147. PubMed ID: 32811837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
    Järås M; Johnels P; Hansen N; Agerstam H; Tsapogas P; Rissler M; Lassen C; Olofsson T; Bjerrum OW; Richter J; Fioretos T
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16280-5. PubMed ID: 20805474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
    Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
    Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.